Novel amide-based inhibitors of inosine 5′-monophosphate dehydrogenase
摘要:
A series of novel amide-based small molecule inhibitors of inosine monophosphate dehydrogenase (IMPDH) was explored. The synthesis and the structure-activity relationships (SARs) derived from in vitro studies are described. (C) 2002 Elsevier Science Ltd. All rights reserved.
Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain
作者:Richard A Hartz、Vijay T. Ahuja、Susheel J. Nara、C.M. Vijaya Kumar、Jeffrey M. Brown、Linda J. Bristow、Ramkumar Rajamani、Jodi K. Muckelbauer、Daniel Camac、Susan E. Kiefer、Lisa Hunihan、Michael Gulianello、Martin Lewis、Amy Easton、Jonathan S. Lippy、Neha Surti、Sreenivasulu N. Pattipati、Manoj Dokania、Saravanan Elavazhagan、Kumaran Dandapani、Brian D. Hamman、Jason Allen、Walter Kostich、Joanne J. Bronson、John E. Macor、Carolyn D. Dzierba
DOI:10.1021/acs.jmedchem.1c00472
日期:2021.8.12
Effective treatment of chronic pain, in particular neuropathicpain, without the side effects that often accompany currently available treatment options is an area of significant unmetmedicalneed. A phenotypic screen of mouse gene knockouts led to the discovery that adaptor protein 2-associated kinase 1 (AAK1) is a potential therapeutic target for neuropathicpain. The synthesis and optimization
The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, such as transplant rejection and autoimmune diseases.
The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5′ monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.